Repositioning Candidate Details
| Candidate ID: | R1431 |
| Source ID: | DB12077 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Urelumab |
| Synonyms: | Urelumab |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex. |
| CAS Number: | 934823-49-1 |
| Molecular Weight: | |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | -- |
| Targets: | Tumor necrosis factor receptor superfamily member 9 |
| Inclusion Criteria: | Target associated |
